Prognosis of Atrial Fibrillation in Patients with Sympton Data from the REduction of Atherothrombosis for Cont

European Journal of Vascular and Endovascular Surgery 40, 9-16 DOI: 10.1016/j.ejvs.2010.03.003

Citation Report

#	Article	IF	CITATIONS
1	Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. Journal of Thrombosis and Haemostasis, 2011, 9, 1301-1307.	3.8	39
2	Sex-related differences in Japanese patients with peripheral arterial disease. Atherosclerosis, 2011, 219, 846-850.	0.8	28
3	Comparison of Ankle-Brachial Index in Patients With and Without Atrial Fibrillation. Medicina (Lithuania), 2011, 47, 93.	2.0	3
4	Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. Current Cardiovascular Risk Reports, 2011, 5, 457-466.	2.0	0
5	Preventive aspects in peripheral artery disease. Therapeutic Advances in Cardiovascular Disease, 2012, 6, 53-70.	2.1	10
6	β-Blockade: Benefits Beyond Blood Pressure Reduction?. Journal of Clinical Hypertension, 2012, 14, 112-120.	2.0	17
7	Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. International Journal of Cardiology, 2013, 168, 904-909.	1.7	67
8	The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Annals of the Rheumatic Diseases, 2013, 72, 1188-1193.	0.9	119
9	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Annals of Medicine, 2013, 45, 274-290.	3.8	25
10	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. Journal of Thrombosis and Haemostasis, 2013, 11, 975-987.	3.8	47
11	Clinical Predictors of Long-Term Outcomes in Patients With Critical Limb Ischemia Who have Undergone Endovascular Therapy. Angiology, 2014, 65, 315-322.	1.8	25
12	Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. European Heart Journal, 2014, 35, 242-249.	2.2	82
13	Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. Perfusion (United Kingdom), 2014, 29, 265-271.	1.0	6
14	Peripheral Artery Disease Is an Independent Predictor of Mortality After Implantable Cardioverter-Defibrillator Implantation in Patients With Severe Left Ventricular Dysfunction. Angiology, 2014, 65, 507-511.	1.8	0
15	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. Journal of the American Heart Association, 2014, 3, .	3.7	39
16	Immediate results and long-term cardiovascular outcomes of endovascular therapy in octogenarians and nonoctogenarians with peripheral arterial diseases. Clinical Interventions in Aging, 2016, 11, 535.	2.9	11
17	Prognostic Significance of Atrial Fibrillation in Lower Limb Amputee Patients. European Journal of Vascular and Endovascular Surgery, 2016, 52, 823-829.	1.5	3
18	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. Journal of the American Heart Association, 2016, 5, .	3.7	143

	CITATION	Report	
#	Article	IF	CITATIONS
19	Atrial Fibrillation Predicts Cardiovascular Outcome in Hypertensive Patients With Symptomatic Peripheral Artery Disease and Preserved Ejection Fraction. Journal of Clinical Hypertension, 2016, 18, 953-954.	2.0	7
20	Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: A nationwide cohort study. International Journal of Cardiology, 2016, 203, 204-211.	1.7	31
21	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. Journal of the American Heart Association, 2017, 6, .	3.7	34
22	Atrial fibrillation as a prognostic indicator of myocardial infarction and cardiovascular death: a systematic review and meta-analysis. Scientific Reports, 2017, 7, 3360.	3.3	11
23	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace, 2017, 19, 1439-1448.	1.7	47
24	Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. International Journal of Cardiology, 2017, 249, 191-197.	1.7	22
25	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 105-120.	2.1	10
26	Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A metaâ€analysis of prospective studies. Clinical Cardiology, 2017, 40, 1231-1235.	1.8	27
27	Association of Peripheral Artery Disease With Incident Atrial Fibrillation: The ARIC (Atherosclerosis) Tj ETQq0 0	0 rgBT/Ove	erlock 10 Tf 5
28	Arterial hypertension and atrial fibrillation. Journal of Cardiovascular Medicine, 2018, 19, 51-61.	1.5	4
29	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
30	Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	1.5	734
31	Association Between Preoperative Frailty and Mortality in Patients With Critical Limb Ischemia Following Infrainguinal Bypass Surgery ― Usefulness of the Barthel Index ―. Circulation Journal, 2018, 82 267-274.	2, 1.6	38
32	APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN. Rational Pharmacotherapy in Cardiology, 2018, 14, 441-450.	0.8	0
33	Atrial fibrillation in peripheral arterial disease with coexisting coronary artery disease and diabetes mellitus: An intricate association not to be missed!. Clinical Cardiology, 2019, 42, 786-787.	1.8	0

34	Comparison of In-Hospital Outcomes in Patients Having Limb-Revascularization With Versus Without Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1540-1548.	1.6	3
35	The imminent epidemic of atrial fibrillation and its concomitant diseases – Myocardial infarction and heart failure - A cause for concern. International Journal of Cardiology, 2019, 287, 162-173.	1.7	29
36	A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. Angiology, 2020, 71, 303-314.	1.8	13

#	ARTICLE	IF	CITATIONS
37	New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: A metaâ€analysis. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1393-1400.	1.2	3
38	New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: aÂmeta-analysis. Herz, 2020, 46, 352-358.	1.1	0
39	Atrial Fibrillation and Surgical Patients with Peripheral Arterial Disease. Annals of Vascular Surgery, 2020, 67, 411-416.	0.9	2
40	Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. European Journal of Clinical Investigation, 2021, 51, e13431.	3.4	3
41	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORPâ€AF General Longâ€Term Registry. International Journal of Clinical Practice, 2021, 75, e13701.	1.7	3
42	Prognostic Value of the CHA ₂ DS ₂ -VASc Score after Endovascular Therapy for Femoral Popliteal Artery Lesions. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1153-1160.	2.0	5
43	New Risk Stratification in Patients with Femoropopliteal PAD. Can We Fight Against the Poor Prognosis?. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1128-1129.	2.0	1
44	Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Annals of Vascular Surgery, 2021, 72, 1-56.	0.9	23
45	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	4.1	7
46	Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	2.2	76
47	Atrial fibrillation in low- and middle-income countries: a narrative review. European Heart Journal Supplements, 2020, 22, O61-O77.	0.1	22
48	2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. Korean Journal of Medicine, 2018, 93, 110-132.	0.3	6
49	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Current Pharmaceutical Design, 2020, 26, 5953-5968.	1.9	4
50	Molecular genetic markers of atrial fibrillation. Bulletin of Siberian Medicine, 2020, 19, 180-189.	0.3	1
51	Low Ankle-Brachial Index Is Associated With Stroke Recurrence in Ischemic Stroke Patients With Atrial Fibrillation. Frontiers in Neurology, 2021, 12, 705904.	2.4	3
52	The Impact of Atrial Fibrillation on Outcomes of Peripheral Arterial Disease: Analysis of Routinely Collected Primary Care Data. American Journal of Medicine, 2022, 135, 488-492.	1.5	3
53	The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease. Journal of Clinical Medicine, 2022, 11, 1936.	2.4	1
54	Clinical Characteristics and Predictors of Long-Term Prognosis of Acute Peripheral Arterial Ischemia Patients Treated Surgically. International Journal of Environmental Research and Public Health, 2023, 20, 3877.	2.6	Ο

CITATION REPORT

#	Article	IF	CITATIONS
55	Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. European Journal of Vascular and Endovascular Surgery, 2023, 65, 627-689.	1.5	29
56	Establishment and Verification of a Nomogram for Predicting the Probability of New-Onset Atrial Fibrillation After Dual-Chamber Pacemaker Implantation. Texas Heart Institute Journal, 2023, 50, .	0.3	0
57	Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment. Medicina ClÃnica, 2023, 161, 344-350.	0.6	2
58	Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment. Medicina ClÃnica (English Edition), 2023, 161, 344-350.	0.2	Ο